Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.43 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.42 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | GPR174 | Q9BXC1 | 4/20 | 0.41 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447313 | 0.96 | LPAR5 (0.50) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL30888163 | 0.88 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL17528452 | 0.88 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL28659331 | 0.88 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL10664178 | 0.88 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL23016732 | 0.88 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL9286668 | 0.86 | USP2 (0.54) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL10656925 | 0.86 | USP2 (0.59) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL173662 | 0.86 | USP2 (0.54) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL11287326 | 0.86 | USP2 (0.59) | USP2LPAR5LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1361872-A4 | NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS | UNIV VIRGINIA (US) | 2004-05-19 | — | — | EP | claimed |
| EP-1361872-A2 | NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-11-19 | — | — | EP | claimed |
| WO-2002029001-A2 | NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF VIRGINIAN PATENT FOUNDATION (US) | 2002-04-11 | — | — | WO | claimed |
| US-7820703-B2 | Lysophosphatidic acid receptor selective antagonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080318901-A1 | Novel Lysophosphatidic Acid Receptor Selective Antagonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1750722-A2 | NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR SELECTIVE ANTAGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7169818-B2 | Lysophosphatidic acid receptor agonists and antagonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2005115150-A2 | NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR SELECTIVE ANTAGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050107447-A1 | Novel lysophosphatidic acid receptor agonists and antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-05-19 | — | — | US | disclosed |
| US-20040122236-A1 | Novel lysophosphatidic acid receptor agonists and antagonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107447-A1 | Novel lysophosphatidic acid receptor agonists and antagonists | LPAR3, LPAR2, LPAR1 | USP2 3149/4885LPAR5 5/4885LPAR3 1/4885 |
| US-20040122236-A1 | Novel lysophosphatidic acid receptor agonists and antagonists | LPAR3, LPAR2, LPAR1 | USP2 3149/4885LPAR5 5/4885LPAR3 1/4885 |
| US-20080318901-A1 | Novel Lysophosphatidic Acid Receptor Selective Antagonists | LPAR3, LPAR2, LPAR1 | USP2 3132/4885LPAR5 5/4885LPAR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.